For research use only
| Cat No. | ABC-TC0063 |
| Product Type | Rat Nerve Tumors Cell Lines |
| Species | Rat – BD-1X Rat |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Malignant Glioma |
| Product Code | B23, B 23, b-23 |
Tumorigenecity: Isoenzyme: Histopathology: astrocytomaSubculture: Split ratio: Media change: Reverse transcritase: Production
B-23 is a rat glioma-derived tumor cell line established from a malignant astrocytoma in BD-1X rats. It exhibits classical astrocytic morphology with elongated, multipolar cells and adherent monolayer growth under standard in vitro conditions. Histopathological analysis confirms high-grade astrocytoma features, including pleomorphism, mitotic activity, and nuclear atypia. B-23 demonstrates tumorigenicity when transplanted into syngeneic rats, forming aggressive intracranial or subcutaneous tumors with infiltrative behavior. The line expresses glial fibrillary acidic protein (GFAP), S100, and vimentin. B-23 is widely used for studying astrocytoma progression, neural invasion, and glioma immunology.The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | B23, B 23, b-23 |
| Species | Rat – BD-1X Rat |
| Cat.No | ABC-TC0063 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Malignant Glioma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Nerve Tumors Cell Lines |
B-23 is an effective model for malignant glioma research, particularly for studies focused on astrocytoma biology, immune evasion, and therapeutic resistance. Its rat origin allows use in syngeneic BD-1X models, enabling immunocompetent glioma investigations. B-23 supports in vitro analysis of glioma cell proliferation, migration, invasion under defined B-23 growth conditions, and can be used in orthotopic or ectopic tumor implantation studies. It is ideal for screening chemotherapeutics, radiation sensitizers, and immunotherapies targeting high-grade astrocytomas. The line’s glial marker expression and reproducible tumorigenicity provide a robust platform for elucidating glioma progression and testing new treatment strategies in translational neuro-oncology research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
